August 1, 2020
Treventis attends Virtual AAIC 2020
Treventis was well represented at the Alzheimer Association International Conference, running from Jul 27-31, 2020 (originally scheduled for Amsterdam, the…
July 8, 2020
Treventis founders awarded funding for COVID-19 clinical trial
LifeArc, a major UK-based charity, has announced funding for Treventis founders Dr. Donald Weaver, Christopher Barden, and Mark Reed to…
June 13, 2020
Treventis attends Virtual BIO Conference
Not to be deterred by COVID-19, Treventis attended the BIO Digital International Convention (formerly scheduled for San Diego, California; instead…
February 25, 2020
Treventis attends 8th Neurodegenerative Drug Development Summit
Treventis CSO Mark Reed was in attendance at the 8th Neurodegenerative Drug Development Summit (previously known as World CNS) held…
February 12, 2020
Treventis Attends Tau2020 Conference
Treventis VP Research Marcia Taylor has attended Tau2020 in Washington, DC, which is one of the world’s biggest conferences focusing…
December 13, 2019
Treventis founders publish new computational methodology for brain drug design
Treventis founders Dr. Donald Weaver, Mark Reed, and Christopher Barden have supervised research at Toronto hospital UHN into new methods…
[siteorigin_widget class=”WP_Widget_Custom_HTML”][/siteorigin_widget]